论文部分内容阅读
目的探讨盐酸羟考酮缓释片治疗中重度癌痛的临床价值。方法选择2010年1月至2013年6月晚期恶性肿瘤患者80例,按随机数字表法分为两组,各40例。对照组使用氨酚羟考酮片5 mg,口服,每12小时1次,每次1片;观察组使用盐酸羟考酮缓释片每日晨服10 mg,每12小时1次,每次1片。比较两组患者治疗后不良反应以及治疗后24 h疼痛VAS评分。结果观察组胃肠道不适、循环抑制、呼吸抑制及头晕的发生率均显著低于对照组(P<0.01或P<0.05),观察组从用药后4 h开始,其疼痛VAS评分即显著低于对照组(P均<0.01)。结论盐酸羟考酮缓释片治疗中重度癌痛,临床作用时间较持久,且不良反应更少,整体效果优于氨酚羟考酮片。
Objective To investigate the clinical value of oxycodone hydrochloride sustained-release tablets in the treatment of moderate-severe cancer pain. Methods Eighty patients with advanced malignant tumors from January 2010 to June 2013 were randomly divided into two groups (n = 40). The control group used oxycodone 5 mg orally, once every 12 hours, 1 tablet each time. The observation group was treated with oxycodone HCl 10 mg daily for 12 hours every time 1. Adverse reactions after treatment and pain VAS scores at 24 h after treatment were compared between the two groups. Results The incidences of gastrointestinal discomfort, circulation inhibition, respiratory depression and dizziness in the observation group were significantly lower than those in the control group (P <0.01 or P <0.05). The VAS score of the observation group was significantly lower 4 h after treatment In control group (all P <0.01). Conclusion Oxycodone hydrochloride sustained-release tablets in the treatment of moderate to severe cancer pain, the longer duration of clinical action, and fewer adverse reactions, the overall effect is superior to oxycodone tablets.